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Abstract 
 
 
Background: Current treatments for schizophrenia, while effective, often lead to 
partial functional recovery for affected individuals. The neurobiology of 
schizophrenia consists of a complex array of factors whose interplay is not well 
understood. As a consequence, schizophrenia remains sub-optimally treated by 
existing therapeutic options. With a paucity of available novel therapies for 
schizophrenia and a lack of biologically driven targets being explored by 
pharmaceutical companies, there is a need for investigator-initiated trials examining 
novel pathways for the reduction of core symptoms and improved functionality. A 
review of the literature identifies the presence of mitochondrial dysfunction, 
oxidative stress and impaired redox defenses such as reduced glutathione levels and 
impaired antioxidant enzymes (glutathione S-transferase) in the primary disorder. 
Secondary metabolites in mangosteen pericarp are hypothesised to protect against 
oxidative stress by evoking an intrinsic pathway including mitochondria. It is unclear 
whether mangosteen pericarp may affect the severity of negative and positive 
symptoms and cognitive and social functioning in schizophrenia. These symptom 
domains are known to persist despite wide use of existing treatment options. The 
current study aims to assess whether adjunctive treatment with mangosteen pericarp 
influences these residual symptom domains in individuals with schizophrenia.  
 
Methods: A randomised, placebo-controlled adjunctive trial was conducted. 
Structured interviews using the Mini International Neuropsychiatric Interview 
(MINI-plus) were conducted to establish the diagnosis of schizophrenia or 
schizoaffective disorder. The efficacy of the intervention on symptom domains was 
assessed using established outcome measures, consisting of structured interviews at 
baseline, 90 days, 150 days and 180 days. The primary outcome measure was the 
Positive and Negative Syndrome Scale (PANSS) total score, with secondary 
measures including the PANSS subscales (positive, negative and general), the 
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Montgomery Asberg Depression Rating Scale (MADRS), the Clinical Global 
Impression Improvement (CGI-I) and Severity scales (CGI-S), the Abnormal 
Involuntary Movement Scale (AIMS), the Self-Rated Life Satisfaction Scale (SRLS), 
the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) and the 
Global Assessment of Functioning (GAF). It was hypothesised that adjunctive 
mangosteen pericarp would reduce symptoms of schizophrenia indexed by PANSS 
total scores compared to placebo. The study followed Good Clinical Practice and 
National Health and Medical Research Council guidelines for clinical trials. 
Participants were randomly allocated to either 1000mg/day of encapsulated Garcinia 
mangostana L. (mangosteen) pericarp powder or a matching placebo for a period of 
180 days, in addition to treatment as usual.  
 
Results: The primary and secondary measures were assessed at each interview. The 
placebo and experimental group had statistically significant differences between 
groups on the primary and secondary outcomes at the 180-day endpoint. The efficacy 
of mangosteen pericarp was supported by a high level of compliance and significant 
difference of the primary indicator, PANSS total (p < 0.01), with a large effect size 
(1.41) between groups at endpoint.  
 
Secondary measures demonstrated significant between-group differences across all 
measures of dimensional outcome: PANSS positive (p < 0.01), PANSS negative (p < 
0.01), PANSS general (p < 0.01), MADRS (p = 0.01) and CGI-S (p = 0.03). 
Functioning and well-being measures were significantly different between groups for 
SRLS (p < 0.01) and GAF (p = 0.03). The effect of treatment over time was different 
between groups, as measured by CGI-I (p < 0.01). Side-effect rating across 
LUNSERS scores indicated significant between-group differences (p < 0.01), with 
greater reduction in the mangosteen pericarp group. There were non-significant 
differences between groups of tardive dyskinesia (p = 0.16) measured by AIMS 
scores. Tobacco and alcohol use did not differ between groups at 180 days. 
Mangosteen pericarp was well tolerated.   
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Conclusions: Our data supports a causal relationship between mangosteen pericarp 
and a reduction of symptom domains associated with schizophrenia. Our results 
support the efficacy of 1000mg/day encapsulated mangosteen pericarp compared to 
the placebo for the treatment of schizophrenia and schizoaffective disorder.  
 
Australian and New Zealand Clinical Trial Registration number: 
ACTRN12611000910909.  
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